(VIANEWS) – The Market ended the session with ULTIMOVACS (ULTI.OL) jumping 14.6% to kr2.59 on Monday while Oslo Børs Benchmark Index_GI jumped 0.49% to kr1,392.67.
ULTIMOVACS’s last close was kr2.26, 98.73% under its 52-week high of kr178.60.
About ULTIMOVACS
Ultimovacs ASA, a biotech company, develops immunotherapies against cancers in Norway. Its lead product candidate is UV1, a peptide-based therapeutic cancer vaccine that induces a specific T cell response against the pan-tumor antigen telomerase. Ultimovacs ASA was incorporated in 2011 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, ULTIMOVACS has a trailing twelve months EPS of kr-5.2.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -59.69%.
Volatility
ULTIMOVACS’s last week, last month’s, and last quarter’s current intraday variation average was a negative 5.79%, a negative 2.16%, and a positive 3.75%.
ULTIMOVACS’s highest amplitude of average volatility was 5.79% (last week), 4.41% (last month), and 3.75% (last quarter).
Moving Average
ULTIMOVACS’s value is way below its 50-day moving average of kr5.59 and way below its 200-day moving average of kr51.73.
More news about ULTIMOVACS (ULTI.OL).
